Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

11 Customer Reviews

  • FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

    Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

    SK-HEP-1 cells were plated in the presence or absence of the CDK inhibitor (Roscovitine 10 mM; Palbociclib 500 nM). 18 hours after plating, cells were rinsed once with serum-free medium and incubated with delipidated medium containing the CDK inhibitor for 6 hours.

    Cell, 2018, doi:10.1016/j.cell.2018.11.011. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)		 CDK4/CyclinD1 [1]
(Cell-free assay)		 CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MYnLbY5ie2ViQYPzZZk> MorCNlQhcA>? MU\Jcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>? NITLSFEzPDZ2MUGwNy=>
COLO205 M3G2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hqb|czKGh? M1jMSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO NFjLVm8zPDZ2MUGwNy=>
U937 M4G2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXSeIw4OiCq MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN M2rEdFI1PjRzMUCz
MOLM13 NWW3blNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:2ZVczKGh? NYX6[HlLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? NUS2Z|lzOjR4NEGxNFM>
MOLM13 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3vO5Q4OiCq NILCfmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP MV:yOFY1OTFyMx?=
MDA-MB-435 NUPZRZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ja[VI1KGh? NXHxfGdrUUN3ME2wMlE3KM7:TR?= NGTDR3UyPThyMUizNS=>
K562 MV\DfZRwfG:6aXOgRZN{[Xl? M1u5dFk3KGh? NF\Z[npFVVOR MmHjTWM2OD1{IN88US=> M2PVWFI1PDF5NU[2
DU145 MWfDfZRwfG:6aXOgRZN{[Xl? NXLtfnIzQTZiaB?= MXnEUXNQ MWnJR|UxRTdwNTFOwG0> MUCyOFQyPzV4Nh?=
MDA-MB-231 NYDFUoxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWxJO69VQ>? MVeyOEBp NVjJeYFITE2VTx?= NWnRSpk1S2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MXqyOFQyPzV4Nh?=
MCF7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLjXo4yKM7:TR?= MXOyOEBp MnjUSG1UVw>? MnLrR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NYXyS5NnOjR2MUe1OlY>
MCF7 MVTLbY5ie2ViQYPzZZk> Ml\wOUDPxE1? NVHxNJhiOjRiaB?= MYXEUXNQ MmLETY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= MYGyOFQyPzV4Nh?=
MDA-MB-231 M13PbGtqdmG|ZTDBd5NigQ>? NGjCenM2KM7:TR?= NHfrZ|MzPCCq MnTKSG1UVw>? MnPLTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NFHvWXQzPDRzN{W2Oi=>
MDA-MB-231 NX3QV4s5TnWwY4Tpc44hSXO|YYm= M4PLRVEuOTBizszN MlHNNlQhcA>? M33pcmROW09? NXPDXZJL\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl M1vNd|I1PDF5NU[2
MCF7 NF36U4FHfW6ldHnvckBCe3OjeR?= NUPUeYtzOS1zMDFOwG0> M1fFclI1KGh? NF\wSWJFVVOR NWnFfpE{\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl NY\jbZNQOjR2MUe1OlY>
MDA-MB-231 NUW4SnFMTnWwY4Tpc44hSXO|YYm= MoPBNE42NTFizszN NIK4RmI1QCCq Mk\USG1UVw>? M4fSVohieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MYiyOFQyPzV4Nh?=
MCF7 NVra[VBRTnWwY4Tpc44hSXO|YYm= MXmwMlUuOSEQvF2= MlXzOFghcA>? MoTiSG1UVw>? NIL3Xmpp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? MofWNlQ1OTd3Nk[=
697 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;xO5ZKSzVyPUG0PE4{QCCwTR?= NIjrW2xUSU6JRWK=
P12-ICHIKAWA NVHndotbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfZd2lKSzVyPUm2MlA1KG6P MknKV2FPT0WU
NB69 NX3RXo86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3sZWJKSzVyPUG2NU45KG6P MkTOV2FPT0WU
EoL-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rlT2lEPTB;MUi3MlI3KG6P Mm[zV2FPT0WU
BHT-101 NV75PFR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPN[2RrUUN3ME2xPVgvOjVibl2= NHvueoZUSU6JRWK=
SK-NEP-1 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLpZXZKSzVyPUKyNE4xOiCwTR?= MXzTRW5ITVJ?
MHH-NB-11 NVewfVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfrdWVMUUN3ME2yNlAvOTlibl2= NGG1THRUSU6JRWK=
AsPC-1 NHTme|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fFTWlEPTB;MkWyMlU{KG6P Ml7QV2FPT0WU
ES1 NYfKZ|hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDhZWhKSzVyPUK1Ok4zPSCwTR?= MUfTRW5ITVJ?
LAMA-84 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHCe41KSzVyPUK1PE4yQSCwTR?= Mm\wV2FPT0WU
MOLT-16 NGnSN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j5fWlEPTB;MkW4MlQ6KG6P M3ThT3NCVkeHUh?=
ES7 M2n4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PL[mlEPTB;MkezMlA6KG6P NFK0[GNUSU6JRWK=
KY821 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n0UGlEPTB;M{G0MlEhdk1? M4DJTXNCVkeHUh?=
RT-112 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PN[GlEPTB;M{KxMlA2KG6P M3m5cXNCVkeHUh?=
HL-60 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml21TWM2OD1|NECuOlYhdk1? NGjGO2VUSU6JRWK=
MOLT-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzJVHVwUUN3ME2zOFUvOTNibl2= MnnRV2FPT0WU
KARPAS-45 M{j6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTmTWM2OD1|N{[uNVYhdk1? NWjhclV{W0GQR1XS
SK-N-AS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDvUJVKSzVyPUO4O{45OyCwTR?= MU\TRW5ITVJ?
CTB-1 NVjsXplzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6yTWM2OD12MEWuNFIhdk1? NEjvVJpUSU6JRWK=
NKM-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG2ZllCUUN3ME20NVEvQDlibl2= M3;mN3NCVkeHUh?=
HTC-C3 NXiwVmgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e0SmlEPTB;NEOyMlk2KG6P NWm5bYVnW0GQR1XS
BE-13 NV3HSo9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln2TWM2OD12NESuNlchdk1? MXvTRW5ITVJ?
KOSC-2 M{Toc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjnToJQUUN3ME20OlYvQSCwTR?= NEK0NoJUSU6JRWK=
NB14 NETTZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\0PGlEPTB;NEizMlU5KG6P MVjTRW5ITVJ?
CAL-27 M4nNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqzTWM2OD12OUSuOVkhdk1? NXe2SnFLW0GQR1XS
H9 NWDMUIMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonZTWM2OD12OUWuOFMhdk1? NXX1[nhPW0GQR1XS
RS4-11 M3\nRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:xNo57UUN3ME21NFQvPzNibl2= MoPNV2FPT0WU
PA-1 M4\Nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13WWGlEPTB;NUC5Mlg3KG6P NX:1WHV{W0GQR1XS
MV-4-11 M{LNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTVzMz64OUBvVQ>? NVvYNmZ2W0GQR1XS
OS-RC-2 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTV{MT62NkBvVQ>? NIOzbY9USU6JRWK=
RPMI-8226 M1j5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XVUmlEPTB;NUK2Mlg3KG6P M1;ZRnNCVkeHUh?=
HGC-27 NXzoNoJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PNOGlEPTB;NU[0Mlk6KG6P NXm5epVWW0GQR1XS
CHP-212 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfLTWM2OD13OUOuOVkhdk1? M2rDbHNCVkeHUh?=
NB10 M4noNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTBTWM2OD13OUmuNVghdk1? M2rOWXNCVkeHUh?=
HH MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn2[mVKSzVyPUW5PU41OyCwTR?= NETxVZJUSU6JRWK=
EW-16 NVzIZY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEntR5pKSzVyPU[wN{42OiCwTR?= M4LWZnNCVkeHUh?=
ES8 NXHxbGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSxTWM2OD14MEWuNlEhdk1? MXXTRW5ITVJ?
HAL-01 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7MNnI4UUN3ME22NFUvPjdibl2= M4jwbXNCVkeHUh?=
A204 NXTJe|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHHUlNSUUN3ME22N|MvQTFibl2= M2fufnNCVkeHUh?=
MHH-PREB-1 NI[2N5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHHUHFYUUN3ME22N|YvQTlibl2= NIX0[ppUSU6JRWK=
EM-2 NF3ucWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvVTWM2OD14NUCuOlQhdk1? Mn;JV2FPT0WU
BV-173 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjGNXdKSzVyPU[1Nk41QCCwTR?= MWPTRW5ITVJ?
ONS-76 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWryTXpOUUN3ME22O|cvQDJibl2= Mlj5V2FPT0WU
KM-H2 M37Oemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLxOlQxUUN3ME22PVUvPTRibl2= NWexV4xMW0GQR1XS
D-263MG M1LDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HIbmlEPTB;N{G3MlEzKG6P MnHRV2FPT0WU
ES3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jYUGlEPTB;N{K4Mlk{KG6P M3vqN3NCVkeHUh?=
VA-ES-BJ MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[yU2lEPTB;N{OyMlI4KG6P NXrZPGdrW0GQR1XS
NBsusSR MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTd2Mj65PUBvVQ>? NULzNIM5W0GQR1XS
NCI-H520 NVvjTY5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7QTWM2OD15NE[uOVIhdk1? MlnOV2FPT0WU
ES5 M4e3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfSNJRKSzVyPUe1Nk45KG6P MV3TRW5ITVJ?
T-24 NVXG[GFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn2PFZKSzVyPUe3PE44OSCwTR?= MV;TRW5ITVJ?
SW962 NFzHPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC0TWM2OD16MEiuOlMhdk1? M3P0dnNCVkeHUh?=
EW-3 NGPB[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTD[WNKSzVyPUiwPE44PiCwTR?= NYPnUFZDW0GQR1XS
RXF393 M4rKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfCUIFKSzVyPUixNk44QSCwTR?= NVzQb2hoW0GQR1XS
U251 NYTVVm5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP0TWM2OD16MUOuPFghdk1? MonyV2FPT0WU
CAMA-1 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPjTWM2OD16M{OuPVQhdk1? MYjTRW5ITVJ?
JVM-3 M1TkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\URVZyUUN3ME24OVEvPzhibl2= NYjzVo01W0GQR1XS
COLO-800 NUH0fo1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrkO3FKSzVyPUi5O{44QCCwTR?= M1:5NnNCVkeHUh?=
OVCAR-5 NXXWO3lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTlyMD6xJI5O NUDOV2hVW0GQR1XS
LB1047-RCC M3vwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTl{Nz61OkBvVQ>? NXm5VXNLW0GQR1XS
SW954 M3y5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXwWoZKSzVyPUmyPU41OSCwTR?= Mni5V2FPT0WU
J-RT3-T3-5 M4OzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nvUWlEPTB;OUO2MlA3KG6P MUfTRW5ITVJ?
Mewo MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HU[2lEPTB;OUO2MlYhdk1? M3P0T3NCVkeHUh?=
NCI-H1770 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTl2MD61OUBvVQ>? NX7H[4FkW0GQR1XS
HO-1-N-1 NE\1eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\1ZY1KSzVyPUm2Nk45OSCwTR?= M2jkXnNCVkeHUh?=
HSC-3 NEXMSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXXGlEPTB;OU[2MlQ5KG6P NGSwSnJUSU6JRWK=
TYK-nu M{OwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PxXGlEPTB;OUm4MlI2KG6P Mn:yV2FPT0WU
KYSE-150 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwMECwO|Yh|ryP MXrTRW5ITVJ?
SN12C NWDqUFh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwMEC4O|Uh|ryP NHHrVYZUSU6JRWK=
MOLT-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn4TWM2OD1zLkCxOFIyKM7:TR?= NX\1TFR6W0GQR1XS
TE-11 NHrGSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj3eJhRUUN3ME2xMlA1QDF{IN88US=> M2O0[3NCVkeHUh?=
DB MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwMEeyO|Mh|ryP M2DBfHNCVkeHUh?=
CAL-39 M3nYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDjeXdKSzVyPUGuNFc2OjJizszN M3vMbXNCVkeHUh?=
A3-KAW M4TK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\pTmlEPTB;MT6wPFQxQCEQvF2= Ml3CV2FPT0WU
CHP-134 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zWSGlEPTB;MT6xNVgxPyEQvF2= MlLYV2FPT0WU
TGW Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjoTWM2OD1zLkGyN|k2KM7:TR?= NUXkTVhzW0GQR1XS
QIMR-WIL NFz0Z|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLvTWM2OD1zLkGzNVM1KM7:TR?= NF;DSIhUSU6JRWK=
NCI-SNU-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XITWlEPTB;MT6xOlM2PCEQvF2= MUfTRW5ITVJ?
CGTH-W-1 NUXm[mc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjKdlZKSzVyPUGuNVcyQDZizszN MVnTRW5ITVJ?
MHH-ES-1 M3voPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TZV2lEPTB;MT6xO|k5PiEQvF2= M4i0bnNCVkeHUh?=
LB2241-RCC NIi4NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTzUYszUUN3ME2xMlE5PjJizszN Mn3KV2FPT0WU
ML-2 M{fvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\xTWM2OD1zLkKwO|M1KM7:TR?= NYG0OGgzW0GQR1XS
COR-L23 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO4d5VDUUN3ME2xMlIzQTN|IN88US=> MWrTRW5ITVJ?
BFTC-905 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHtNlZKSzVyPUGuNlQzPjdizszN MnqyV2FPT0WU
Hs-578-T NIPx[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwMkW4NVch|ryP MUDTRW5ITVJ?
KG-1 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KzTWlEPTB;MT6yOlY5PiEQvF2= M2LneXNCVkeHUh?=
HEL M{XUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPhTWM2OD1zLkK5N|M5KM7:TR?= NEnZ[nlUSU6JRWK=
A549 NGHWNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ewS2lEPTB;MT6yPVM6QSEQvF2= M33yZnNCVkeHUh?=
COLO-741 M4fRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwM{KwPFkh|ryP NYO0NY5kW0GQR1XS
PC-3 NHrB[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7nTWM2OD1zLkO1NlIyKM7:TR?= NHjHc2NUSU6JRWK=
HOS Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle2TWM2OD1zLkO1Nlk3KM7:TR?= NHTmfnBUSU6JRWK=
HT-1080 NILo[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPUW3JKSzVyPUGuN|c2OTlizszN M2DMfHNCVkeHUh?=
TE-8 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXraeYIyUUN3ME2xMlQyPzd2IN88US=> MYfTRW5ITVJ?
BHY MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvSGlEPTB;MT60OlkzOyEQvF2= M4rHOXNCVkeHUh?=
BB65-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LibWlEPTB;MT61NFUzQCEQvF2= NEXjem9USU6JRWK=
HN NInCbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnVV2lkUUN3ME2xMlU1ODdzIN88US=> MlPtV2FPT0WU
NCI-H441 NIHZUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljJTWM2OD1zLkW0PVA4KM7:TR?= NY\0RXp{W0GQR1XS
RPMI-8866 NEPhPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf1TWM2OD1zLkW4OVA4KM7:TR?= MXLTRW5ITVJ?
CAL-62 NX3v[nhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwNkC4OlIh|ryP NEL2N2tUSU6JRWK=
MG-63 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\HTWM2OD1zLk[xPFE{KM7:TR?= M{LrRXNCVkeHUh?=
SK-LU-1 M3XsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwV4tKSzVyPUGuOlIyPTJizszN M2rtfHNCVkeHUh?=
BCPAP M2SxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwNk[0OVch|ryP MknqV2FPT0WU
22RV1 NHrMPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHFd4hKSzVyPUGuOlc5PDNizszN MVrTRW5ITVJ?
T47D NYLx[HdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fhTGlEPTB;MT62PFA3OSEQvF2= MVTTRW5ITVJ?
MSTO-211H NIXaTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2ZmlEPTB;MT62PVYxOyEQvF2= M1vweHNCVkeHUh?=
DEL MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fUb2lEPTB;MT63NFI4OyEQvF2= MlLvV2FPT0WU
H4 NEXW[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwN{OyNVIh|ryP NVm2XmhkW0GQR1XS
CAL-51 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17pWmlEPTB;MT63OFg2PSEQvF2= NIfGO5RUSU6JRWK=
ABC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXmcpJbUUN3ME2xMlc5PTh{IN88US=> MUfTRW5ITVJ?
MZ2-MEL NGLIPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjKO3FzUUN3ME2xMlc6PTR{IN88US=> NFr3RoNUSU6JRWK=
YKG-1 NFK1WJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwOEGwOlEh|ryP MUfTRW5ITVJ?
KM12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwOEG2NFIh|ryP NWi5b4ZvW0GQR1XS
L-363 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:zTWM2OD1zLki3OFEzKM7:TR?= MlfYV2FPT0WU
KU812 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;rNY5KSzVyPUGuPFkzQDJizszN M4f5NnNCVkeHUh?=
LOXIMVI M{Kxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzQTWM2OD1zLkmxNlI5KM7:TR?= MmjJV2FPT0WU
G-401 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfkdldKSzVyPUGuPVI1OjhizszN NF;vcXNUSU6JRWK=
SW780 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4focGlEPTB;MT65OlI1PiEQvF2= Ml7nV2FPT0WU
SW872 NW\W[|hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3TWM2OD1zLkm4N|Mh|ryP MXLTRW5ITVJ?
NB7 NGnoR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PvdWlEPTB;MT65PVMzOyEQvF2= MofDV2FPT0WU
T98G NF;mSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwMEC2OlYh|ryP MV3TRW5ITVJ?
SW1710 NFvnfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5[2lEPTB;Mj6wOlk1PSEQvF2= NWD2OpRmW0GQR1XS
NCI-H1573 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Pjb2lEPTB;Mj6wO|I6QCEQvF2= NXjPNVBqW0GQR1XS
KE-37 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwMEi5OVEh|ryP NYriSXR{W0GQR1XS
786-0 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPZZ5VKSzVyPUKuNVU1OzlizszN Mn[3V2FPT0WU
SAS Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqzR4FKSzVyPUKuNlA{PzRizszN NEjMXZhUSU6JRWK=
CAL-54 M1[0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTr[WtSUUN3ME2yMlIxPDF|IN88US=> NInwdHBUSU6JRWK=
SF268 NFTs[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwMkOxNlIh|ryP M{X5VHNCVkeHUh?=
SW620 NYHtfHo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwMk[xOlkh|ryP NIDBTG1USU6JRWK=
MN-60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPiTWM2OD1{LkOxNFYh|ryP NWHW[Zg2W0GQR1XS
EFO-27 NHvTd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD0TWM2OD1{LkOyNFU5KM7:TR?= MVPTRW5ITVJ?
NCI-H747 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW3TWM2OD1{LkOyNVk6KM7:TR?= MY\TRW5ITVJ?
HCC2218 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe4PHZkUUN3ME2yMlM2Ozd2IN88US=> NW[2eYZZW0GQR1XS
MIA-PaCa-2 NV7hNIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJwM{[0N|ch|ryP MXXTRW5ITVJ?
SJSA-1 NFTGZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\LbGlEPTB;Mj6zO|c6PiEQvF2= NXi2dIpIW0GQR1XS
RKO M33oWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LxWGlEPTB;Mj6zPFQ6PiEQvF2= M2m2[3NCVkeHUh?=
NB6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1{LkSwN|c1KM7:TR?= NIjsZZdUSU6JRWK=
ES4 NWHqbotLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDGTWM2OD1{LkS1OFIzKM7:TR?= MkL2V2FPT0WU
EGI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnhboRMUUN3ME2yMlQ3QDh|IN88US=> MXXTRW5ITVJ?
CTV-1 NGe5THVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LWT2lEPTB;Mj61Nlc4OyEQvF2= M3K5UXNCVkeHUh?=
NCI-H1355 M2PDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHOTWM2OD1{LkW1PVUyKM7:TR?= NF;rc4RUSU6JRWK=
GT3TKB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwNUmxPVkh|ryP M3y2eHNCVkeHUh?=
SK-HEP-1 NWL3cHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;nT3BNUUN3ME2yMlU6OjZ4IN88US=> M2\SR3NCVkeHUh?=
GAMG NG\1N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jISGlEPTB;Mj61PVM6PCEQvF2= MnTwV2FPT0WU
SK-MES-1 M2PhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O1OmlEPTB;Mj62NVgxOyEQvF2= MWrTRW5ITVJ?
RO82-W-1 M1vZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3MZY9bUUN3ME2yMlYzODV5IN88US=> M{PVWXNCVkeHUh?=
ECC10 NUfzNHFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7zTWM2OD1{LkewNlA3KM7:TR?= NXXhVI1NW0GQR1XS
MCF7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwN{G0OlQh|ryP NHWyS2VUSU6JRWK=
D-283MED M1q5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvQW2tzUUN3ME2yMlczPDNizszN MWTTRW5ITVJ?
RPMI-7951 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rTSGlEPTB;Mj63OVY6PCEQvF2= M1PHe3NCVkeHUh?=
Ramos-2G6-4C10 M17zdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uzZ2lEPTB;Mj63O|A6QSEQvF2= Mm\uV2FPT0WU
KGN NHTmNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7lUIFNUUN3ME2yMlgyQDh2IN88US=> MlnjV2FPT0WU
NUGC-3 NF:zO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn1e|dKSzVyPUKuPFI2ODVizszN M{\vU3NCVkeHUh?=
NCI-H292 M3zsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;1dlFjUUN3ME2yMlg2ODV|IN88US=> NVnVeGdmW0GQR1XS
Becker MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJenhKSzVyPUKuPVU5OzJizszN Mo\PV2FPT0WU
NCI-H1299 NVj4OGRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\lU2lEPTB;Mz6wOVI3OyEQvF2= NGO1WolUSU6JRWK=
ETK-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwMEW0N{DPxE1? Mle1V2FPT0WU
TK10 NGnZPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuSmlEPTB;Mz6yNFE3PSEQvF2= MlnKV2FPT0WU
VMRC-RCZ M{\2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwM{[0PFgh|ryP MoDZV2FPT0WU
YH-13 NGnE[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M134PGlEPTB;Mz60OFA4QSEQvF2= NF\wbWhUSU6JRWK=
DU-145 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTWfG1KSzVyPUOuOFYzPjlizszN NXjw[ZNlW0GQR1XS
SW1088 M{\lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNwNEe0O{DPxE1? MVPTRW5ITVJ?
HOP-92 M1rRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmeyTWM2OD1|LkWwN|QzKM7:TR?= NULXemJYW0GQR1XS
KP-N-YS NVzFR49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNwNkKxN|kh|ryP NXX4NZExW0GQR1XS
NCI-H460 NYXndottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLNTWM2OD1|Lk[2O|Mh|ryP MWTTRW5ITVJ?
U-2-OS NFzobpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPwTWM2OD1|LkeyOVM2KM7:TR?= M{jSbHNCVkeHUh?=
A101D M3\G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXTZohtUUN3ME2zMlc3QTN4IN88US=> MnjyV2FPT0WU
MDA-MB-231 NIf4UFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Z[W5KSzVyPUOuPFE6PTFizszN NWmycmFsW0GQR1XS
IST-MES1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDweYJKSzVyPUOuPFMzKM7:TR?= NEX6[mdUSU6JRWK=
COR-L105 NGrTNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HkSmlEPTB;ND6wNVgh|ryP MmmwV2FPT0WU
NCI-H1437 M4PRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6xO|ljUUN3ME20MlAzOzB{IN88US=> NWjTbZZiW0GQR1XS
CAL-85-1 NGKxXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHDeotxUUN3ME20MlAzPDZzIN88US=> MYLTRW5ITVJ?
MZ1-PC Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwMUi1OVYh|ryP M4LQVnNCVkeHUh?=
VM-CUB-1 M3vsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vPZmlEPTB;ND6zNVI5PCEQvF2= MlLwV2FPT0WU
CHL-1 NHWwdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrBT|ZKSzVyPUSuN|IyPjlizszN MWXTRW5ITVJ?
MDA-MB-361 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnWZZdKSzVyPUSuN|MyPTNizszN MUTTRW5ITVJ?
NCI-H661 NX3pZWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfRTWM2OD12LkWwNFkzKM7:TR?= NEnjR2xUSU6JRWK=
EW-11 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rR[mlEPTB;ND61NlI{OSEQvF2= NHnZflBUSU6JRWK=
BEN NF;C[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP0O5pKSzVyPUSuOVI5OTVizszN MlPFV2FPT0WU
BFTC-909 NYnldGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHpfmNTUUN3ME20MlU3Ojd3IN88US=> Mn3oV2FPT0WU
NCI-H2087 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL6TWM2OD12LkW4NVY1KM7:TR?= MkHhV2FPT0WU
RVH-421 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK5c3VKSzVyPUSuOlY3QSEQvF2= NFvkemxUSU6JRWK=
P30-OHK MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;jeGlEPTB;ND62PFAxQCEQvF2= MoDoV2FPT0WU
NCI-H28 NHuxO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HOcWlEPTB;ND64NVY3OSEQvF2= Mn;yV2FPT0WU
ES6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK3TWM2OD12LkizNFE3KM7:TR?= NY\DUVg5W0GQR1XS
769-P MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojpTWM2OD12Lki1PVI3KM7:TR?= MmjPV2FPT0WU
OE33 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17RTWlEPTB;ND64PFE3OSEQvF2= Ml\zV2FPT0WU
SW982 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LzOGlEPTB;ND65OVA3OSEQvF2= MoHuV2FPT0WU
A388 NWnoNpRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\RTGlEPTB;NT6wNlk5OyEQvF2= Mlq1V2FPT0WU
TI-73 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PPWGlEPTB;NT6wOlE6PCEQvF2= NYnLU4xNW0GQR1XS
HCT-116 NGjLd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2ZmlEPTB;NT6wPVg5QSEQvF2= NULjWZp1W0GQR1XS
HuP-T3 NUW1eoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7GN2l2UUN3ME21MlE5PzB7IN88US=> M4HuTHNCVkeHUh?=
G-402 M{f6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm1cWhKSzVyPUWuNVk1OTZizszN M3j6TXNCVkeHUh?=
NCI-H1792 M3jYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDpenZKSzVyPUWuNlQ3OjJizszN NYrlS2lGW0GQR1XS
NCI-H209 NFLmOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwMkW5OFIh|ryP M4XhT3NCVkeHUh?=
NCI-H1650 M{Dyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nqZWlEPTB;NT6zNFY{PCEQvF2= MUjTRW5ITVJ?
LCLC-97TM1 M1XVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOxNFlKSzVyPUWuN|E5ODhizszN NETL[IJUSU6JRWK=
S-117 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpeoRKSzVyPUWuN|Y6PzZizszN M4\tZ3NCVkeHUh?=
GI-ME-N MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTVwM{m2PFEh|ryP MWLTRW5ITVJ?
NCI-H2122 M{C0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTVwNEmzPVch|ryP M1;PTnNCVkeHUh?=
NCI-H1793 NEDnd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\pSIxkUUN3ME21MlY4PTl|IN88US=> NGDve49USU6JRWK=
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXSRmZKSzVyPUWuO|AxQDhizszN M1H2UHNCVkeHUh?=
TE-12 M3;sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTZTWM2OD13LkiwOVU3KM7:TR?= M4PrNnNCVkeHUh?=
LCLC-103H MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHKU4h{UUN3ME21MlkyPyEQvF2= M3\FTXNCVkeHUh?=
A673 M1n6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIXFNKSzVyPUWuPVE6OzJizszN M{HENXNCVkeHUh?=
BB30-HNC M17JTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTVwOUizOkDPxE1? M2PVfnNCVkeHUh?=
SF295 NX7WS2ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZwMEC0NlIh|ryP MnzNV2FPT0WU
KU-19-19 M{HsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfVTWM2OD14LkCxO|MyKM7:TR?= NWPUUIV5W0GQR1XS
CFPAC-1 M1rhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHEc3pKSzVyPU[uNFQ1PDNizszN NV7lT41uW0GQR1XS
LoVo MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO4TWM2OD14LkC1NFY{KM7:TR?= NUPWR2wyW0GQR1XS
8505C MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfKTWM2OD14LkC3OVc{KM7:TR?= M13iOnNCVkeHUh?=
GMS-10 M1v0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwMUWwNFIh|ryP MnzIV2FPT0WU
Ca9-22 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnyTWM2OD14LkG2O|Eh|ryP MlvtV2FPT0WU
DOK M4j4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZwMkKwO|Ih|ryP NX\6cnlEW0GQR1XS
FADU MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jYfWlEPTB;Nj6yOlA{QSEQvF2= NEDvTpBUSU6JRWK=
BxPC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fTeGlEPTB;Nj6yO|MzKM7:TR?= NX\oWJVEW0GQR1XS
CAL-33 MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zON2lEPTB;Nj6yPVIxOSEQvF2= MonaV2FPT0WU
SHP-77 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLNc3NpUUN3ME22MlMyPTF{IN88US=> Mn\xV2FPT0WU
LXF-289 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvsTWM2OD14LkOzOFU2KM7:TR?= MlmzV2FPT0WU
GB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK2UWJOUUN3ME22MlM5OiEQvF2= MmTSV2FPT0WU
KS-1 NUHrTJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrPTWM2OD14LkO4OFQ4KM7:TR?= NX;hSZV[W0GQR1XS
D-502MG NFTMSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnFTWM2OD14LkSyN|c3KM7:TR?= MoXzV2FPT0WU
LAN-6 M2rqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3FSI9KSzVyPU[uOVExOjNizszN MlG0V2FPT0WU
H-EMC-SS M3f4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO2Tox[UUN3ME22MlU3OTR5IN88US=> Ml7zV2FPT0WU
LC-2-ad MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTZwNkCwO|Yh|ryP MVTTRW5ITVJ?
NCI-H1693 NGL4TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG1Zll3UUN3ME22MlYzOjF3IN88US=> NYjDSJpJW0GQR1XS
SK-N-FI NUX2fY1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGyTWM2OD14Lke1NFQ1KM7:TR?= NGXuW5JUSU6JRWK=
D-423MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M365UGlEPTB;Nj63OlEyPyEQvF2= MkLSV2FPT0WU
KNS-42 NEXFRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXhN4o{UUN3ME22Mlc5OTl5IN88US=> MYTTRW5ITVJ?
GCT NH:yW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrCOo9kUUN3ME22Mlk{QCEQvF2= NGDwRZZUSU6JRWK=
DSH1 NVf0V2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTdwME[zN{DPxE1? MlHPV2FPT0WU
D-247MG M1LCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XmNWlEPTB;Nz6wO|g5OSEQvF2= MorEV2FPT0WU
NCI-SNU-5 NXjWVnJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdwMUizO|Eh|ryP NEG3Xm9USU6JRWK=
TE-6 Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\XTWM2OD15LkKwOlAyKM7:TR?= MUnTRW5ITVJ?
NOMO-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;wWWZbUUN3ME23MlIzOTJ5IN88US=> NGLZRVRUSU6JRWK=
NB17 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf6V3ozUUN3ME23MlMxOzB7IN88US=> NEDsOGNUSU6JRWK=
EW-22 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle0TWM2OD15LkO0N|Q5KM7:TR?= M1nZenNCVkeHUh?=
EW-13 NFPYeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\IN5NKSzVyPUeuN|UyPjJizszN NIf0eJFUSU6JRWK=
DOHH-2 M3;IdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT6RZdKSzVyPUeuOFQxOiEQvF2= NX3zUIJFW0GQR1XS
TGBC1TKB NEXadW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DrfmlEPTB;Nz60PVg6QSEQvF2= MX3TRW5ITVJ?
GR-ST NXG2SIljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y0NmlEPTB;Nz61NlU6PCEQvF2= MYDTRW5ITVJ?
KYSE-520 NWTqeIVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn76TWM2OD15LkW1OVE2KM7:TR?= MWHTRW5ITVJ?
CAPAN-1 M3LHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrX[405UUN3ME23MlU6PTFizszN M2jMSnNCVkeHUh?=
HCE-4 M1\6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTdwNkKyO|kh|ryP Mm[yV2FPT0WU
MLMA M2\tPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTdwNkK5OVch|ryP NWPqU|dsW0GQR1XS
HT-144 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjVR|RCUUN3ME23MlY2OzZ6IN88US=> Mnj2V2FPT0WU
KYSE-180 NIfRZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTdwN{GxOlkh|ryP MWHTRW5ITVJ?
TE-5 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TINGlEPTB;Nz65OVk4OSEQvF2= M1T3PXNCVkeHUh?=
IGROV-1 M1T4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf0cXJKSzVyPUeuPVg2PTFizszN MYDTRW5ITVJ?
NCI-H1581 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTaTWM2OD16LkCxNkDPxE1? Ml;CV2FPT0WU
SW1990 M3fneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXyTWM2OD16LkC0OlU6KM7:TR?= MUTTRW5ITVJ?
EFM-19 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnLTWM2OD16LkC4OVQ2KM7:TR?= M2LYXHNCVkeHUh?=
OGR-1 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfMdGJoUUN3ME24MlQ{ODJ|IN88US=> NUK5XI9GW0GQR1XS
U-118-MG M17MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPLTWM2OD16LkSzOFY{KM7:TR?= MmLpV2FPT0WU
SK-OV-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHxWXlQUUN3ME24MlQ3PzZ3IN88US=> NEHve2lUSU6JRWK=
KNS-62 M1rybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfGOXo1UUN3ME24MlUyPzZzIN88US=> NWHycINXW0GQR1XS
GOTO M{PQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwNUe2N|Uh|ryP M2LmPHNCVkeHUh?=
8305C MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRThwN{C0PFQh|ryP M1;QNnNCVkeHUh?=
RPMI-2650 M1HXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\NWlBKSzVyPUiuO|E6PTVizszN NXLWUGVqW0GQR1XS
NEC8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRThwN{SzNFch|ryP MonaV2FPT0WU
KYSE-450 NHnHdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SwT2lEPTB;OD64OlU1QCEQvF2= NYDvS2FiW0GQR1XS
RMG-I MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\FUGlEPTB;OT6xOFA2QCEQvF2= NX;EOXM{W0GQR1XS
CAKI-1 NUezSFR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXScoZPUUN3ME25MlMyQTd7IN88US=> NHXNcopUSU6JRWK=
KYSE-510 M1z5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTlwM{W3O|gh|ryP NVTZWXFuW0GQR1XS
A4-Fuk MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC5PYJWUUN3ME25MlM3PzBzIN88US=> NInSOohUSU6JRWK=
AN3-CA NWPxOJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTETWM2OD17LkS1OFQ1KM7:TR?= MlmyV2FPT0WU
SK-N-DZ MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC2TWM2OD17LkeyPFQ6KM7:TR?= MUnTRW5ITVJ?
HSC-2 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTlwN{[2Nlkh|ryP MXTTRW5ITVJ?
EW-1 NHL6Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjrfHVKSzVyPUmuO|k{PjlizszN MXfTRW5ITVJ?
D-566MG NFTPSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jOdGlEPTB;OT64N|Y3PCEQvF2= MX\TRW5ITVJ?
COLO-792 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPVc3NqUUN3ME25Mlk5PzR4IN88US=> MXjTRW5ITVJ?
TE-10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rYbWlEPTB;MUCuNFM6PiEQvF2= NXG5OHB{W0GQR1XS
NCI-H650 NFvn[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nxNGlEPTB;MUCuOFI5PiEQvF2= MlnsV2FPT0WU
U-266 NITUXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TFU2lEPTB;MUCuOFU2KM7:TR?= M3HtNHNCVkeHUh?=
Detroit562 NFnmenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\tO4s5UUN3ME2xNU4xPTF3IN88US=> MUfTRW5ITVJ?
NH-12 NGS2UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXKTWM2OD1zMT6xOFQ3KM7:TR?= NEPRXVBUSU6JRWK=
CO-314 NIjreVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LiVGlEPTB;MUGuNlg1OiEQvF2= NHXFNY1USU6JRWK=
IST-MEL1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDNTWM2OD1zMT61N|I{KM7:TR?= NIryc|NUSU6JRWK=
KNS-81-FD NGLTWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFzLkW1Nlch|ryP MoLjV2FPT0WU
SW1463 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjLTWM2OD1zMT61PVg6KM7:TR?= MUjTRW5ITVJ?
NCI-H23 NWfUTVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFzLk[1OVIh|ryP MVfTRW5ITVJ?
SK-MEL-2 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\tdGlEPTB;MUGuO|E6PyEQvF2= NF70cHVUSU6JRWK=
NB13 NHzNNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF{LkG0PVUh|ryP NGniUlJUSU6JRWK=
Daoy M13tRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jGWGlEPTB;MUKuNlg2PiEQvF2= NF3Md4VUSU6JRWK=
NCI-H1623 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:2SWlEPTB;MUKuN|gxOSEQvF2= NYTmbXc5W0GQR1XS
NMC-G1 NF;DNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHTWM2OD1zMj63NVch|ryP NGTDSpFUSU6JRWK=
DK-MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP6eJNKSzVyPUGyMlk1QDJizszN NU\nWpgyW0GQR1XS
TCCSUP NYTyUJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF|LkGyPFQh|ryP NGjnNWVUSU6JRWK=
SCC-15 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzvTWM2OD1zMz6yOlUyKM7:TR?= NGDhSGpUSU6JRWK=
NOS-1 NFL0Z2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MniyTWM2OD1zMz6yPFk{KM7:TR?= NVHmZokzW0GQR1XS
RH-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF|LkOwN|ch|ryP MVPTRW5ITVJ?
SK-MEL-3 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF|LkO3Nlgh|ryP MVTTRW5ITVJ?
NB5 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xq[WlEPTB;MUOuOFA3PyEQvF2= MnLtV2FPT0WU
SNU-387 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF|LkWwO|Ih|ryP NI\FTHVUSU6JRWK=
CAL-120 M3XtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLKO21VUUN3ME2xN{43PzF6IN88US=> MV\TRW5ITVJ?
Mo-T NUT6THNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvBTWM2OD1zMz63NFch|ryP NYXTPFJQW0GQR1XS
LNCaP-Clone-FGC M3XQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF|Lke5PVIh|ryP MnXPV2FPT0WU
CAN MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF2LkCyPFgh|ryP NFHabWtUSU6JRWK=
SK-MEL-30 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LrRWlEPTB;MUSuNFY{KM7:TR?= MkjhV2FPT0WU
COLO-678 M1nRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLyTWM2OD1zND6wPFIzKM7:TR?= MWTTRW5ITVJ?
SCC-9 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF2LkGwNlEh|ryP NWe0eYp7W0GQR1XS
KINGS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSzTWM2OD1zND6xOFAzKM7:TR?= MWTTRW5ITVJ?
SL-513 NI\WZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLmTWM2OD1zND6xPFch|ryP M2LGXXNCVkeHUh?=
HLE M{LsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO4TnpKSzVyPUG0MlM5PTJizszN NYDQTXVwW0GQR1XS
SW1573 M2LK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHpfldwUUN3ME2xOE41PDN3IN88US=> NECzRmpUSU6JRWK=
KYSE-140 M{G2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq0TWM2OD1zND62N|I4KM7:TR?= NXHEOFB4W0GQR1XS
SK-PN-DW MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGyWXJ5UUN3ME2xOE45ODBzIN88US=> M2TVN3NCVkeHUh?=
A253 NVLNVXJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGwS3cyUUN3ME2xOU4xPjJ3IN88US=> M3rQXHNCVkeHUh?=
CAL-12T M1;J[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3LkS2OlIh|ryP MWfTRW5ITVJ?
COLO-679 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHpSZlHUUN3ME2xOU44Pjh|IN88US=> MlzwV2FPT0WU
UACC-257 NWrLdXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDGfmhuUUN3ME2xOk4yOjBzIN88US=> MVHTRW5ITVJ?
U-87-MG M333[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q0OWlEPTB;MU[uN|UzOyEQvF2= NGfIdGVUSU6JRWK=
HCC1806 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j2WWlEPTB;MU[uO|A4OSEQvF2= NUf6SWRxW0GQR1XS
NCI-H2170 NFzGU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF5LkK0OFgh|ryP NGGxS5BUSU6JRWK=
AGS NV:5fotCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\jTWM2OD1zNz6zPFA5KM7:TR?= NUPtOXl{W0GQR1XS
MEL-HO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfHTHJKSzVyPUG3Mlc2ODNizszN NGTyfWxUSU6JRWK=
SW48 NX3ROYlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW1Oo1bUUN3ME2xO{44PzF4IN88US=> MkLXV2FPT0WU
HuP-T4 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDhTWM2OD1zOD6wNlA3KM7:TR?= M{DDbnNCVkeHUh?=
NCI-H720 NI\lXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1zOD6xOFAzKM7:TR?= MXzTRW5ITVJ?
RCC10RGB MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfUS5dFUUN3ME2xPE4yPjl5IN88US=> NF7sb41USU6JRWK=
HD-MY-Z Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C1VmlEPTB;MUiuNlI2PCEQvF2= NGTmTYdUSU6JRWK=
A427 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CzeWlEPTB;MUiuOVA6PCEQvF2= MmfRV2FPT0WU
HCC2998 M1vYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy5XnlKSzVyPUG4MlYxPTFizszN MkjlV2FPT0WU
EPLC-272H NFXJWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF7LkC0N|Qh|ryP NWTvPXdlW0GQR1XS
C32 NYTReoExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHWPJlKSzVyPUG5MlA1PSEQvF2= M2TIVnNCVkeHUh?=
UMC-11 NUfQOVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrUTWM2OD1zOT6yNVI{KM7:TR?= MoXDV2FPT0WU
CaR-1 NF7ISGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF7Lk[4NFQh|ryP MXrTRW5ITVJ?
KYSE-410 M1PyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPsSoxxUUN3ME2xPU46OTN7IN88US=> MUPTRW5ITVJ?
HuCCT1 NYfyZ2V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4VGlEPTB;MkCuOlI6PCEQvF2= MnmxV2FPT0WU
LB996-RCC NFjF[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJyLkexOlgh|ryP Mlz2V2FPT0WU
KYSE-70 NVOwe243T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTKb3F[UUN3ME2yNE45ODV7IN88US=> NYrSSFBFW0GQR1XS
CAL-72 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D0bGlEPTB;MkCuPVE2KM7:TR?= M{\wXnNCVkeHUh?=
Capan-2 M{HINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJzLkC0NVMh|ryP MmnOV2FPT0WU
PANC-08-13 NUPCSW9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXJUFhEUUN3ME2yNU4zPTF3IN88US=> MUDTRW5ITVJ?
SBC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWzNmdxUUN3ME2yNU4{ODhzIN88US=> Mm[0V2FPT0WU
MFM-223 NUHofm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nCcGlEPTB;MkGuN|M1OiEQvF2= M4TyZ3NCVkeHUh?=
BB49-HNC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS3TWM2OD1{MT61O|E3KM7:TR?= M3TwXnNCVkeHUh?=
SH-4 NYK4XXJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnTXoVKSzVyPUKxMlY3OThizszN Mk\UV2FPT0WU
HuO9 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PNU2lEPTB;MkGuPVgzPSEQvF2= MVXTRW5ITVJ?
AM-38 NUXkbYZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrFUYdKSzVyPUKyMlA1QDVizszN NV[zd5JKW0GQR1XS
A431 NWLYU3JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O4b2lEPTB;MkOuNlEyQSEQvF2= NVztNYhtW0GQR1XS
YAPC M1nrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\QTWlEPTB;MkOuNlY2OSEQvF2= MlfvV2FPT0WU
LU-139 M4TGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnDOmNKSzVyPUKzMlQ5ODlizszN NV7NVlhzW0GQR1XS
HEC-1 M{npNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ|LkS5N|ch|ryP M{jIRnNCVkeHUh?=
SCC-25 NX3pVGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInmcHVKSzVyPUK0MlMxODZizszN MonSV2FPT0WU
HT-29 NFS1S41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL6W3lPUUN3ME2yOE4{QDJ|IN88US=> NFu4VFZUSU6JRWK=
PC-14 NGLhVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ2Lk[1O|Eh|ryP M{f6RnNCVkeHUh?=
Calu-6 M2TxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jPdWlEPTB;MkWuOVA4OSEQvF2= M4TXOHNCVkeHUh?=
SJRH30 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\COYRMUUN3ME2yOU43PDl4IN88US=> M4LNU3NCVkeHUh?=
ChaGo-K-1 NF;GSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ4LkG2Nlkh|ryP MoTlV2FPT0WU
IA-LM NHf4T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;LTWM2OD1{Nj6zOlQ2KM7:TR?= NYnhdZlXW0GQR1XS
GP5d NED3SWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDh[5Y1UUN3ME2yOk41PDlzIN88US=> NYruRWJIW0GQR1XS
NCI-H2291 NXrZW2FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLRdGo4UUN3ME2yOk43PTRzIN88US=> NVywSINFW0GQR1XS
BALL-1 NYjCSpo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3pOIZKSzVyPUK2Mlk{QTdizszN NFKzbYZUSU6JRWK=
HCC1954 M4PNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ4Lkm4NFgh|ryP NX\0cmpxW0GQR1XS
NCI-H2452 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLUd4xKSzVyPUK3MlQyPjNizszN MoTKV2FPT0WU
LU-99A M2m2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ5LkW1PFIh|ryP NWHqdJROW0GQR1XS
NTERA-S-cl-D1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP0eohKSzVyPUK3MlczQTlizszN NIL6S3hUSU6JRWK=
PANC-10-05 M2HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;HWnFKSzVyPUK3Mlc4PzVizszN M{PxSXNCVkeHUh?=
NCI-H2405 NWW5dVBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[2[phjUUN3ME2yO{46Ozh5IN88US=> NW\5SHdNW0GQR1XS
MDA-MB-415 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PHbGlEPTB;MkiuOFE{PyEQvF2= MU\TRW5ITVJ?
NCI-H2342 M4PLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvrTWM2OD1{OD61NlgyKM7:TR?= MkS5V2FPT0WU
TGBC24TKB NGrweXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH4U3dKSzVyPUK4MlcyOTdizszN MX\TRW5ITVJ?
LU-134-A MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ6LkmyOlEh|ryP MlLHV2FPT0WU
SCC-4 NFeyXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNzLkC0PVQh|ryP NHrEOXVUSU6JRWK=
Saos-2 NFrrfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\JOZRjUUN3ME2zNU46OzB4IN88US=> M4fmc3NCVkeHUh?=
RERF-LC-MS MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN{LkiyN|Eh|ryP NEn5WVBUSU6JRWK=
M14 NH36dG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK1fWV[UUN3ME2zNk46PzZ2IN88US=> NG\G[ndUSU6JRWK=
HPAF-II MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTKb4lwUUN3ME2zN{42ODFzIN88US=> MVvTRW5ITVJ?
NCI-H1755 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfYZ4xTUUN3ME2zOE4{OzB3IN88US=> M3TVT3NCVkeHUh?=
D-392MG NWGwVZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTXeWZLUUN3ME2zOU45Pjd2IN88US=> Ml;NV2FPT0WU
A704 NV;ITYFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DIeWlEPTB;M{[uNFQzPyEQvF2= Mo[xV2FPT0WU
CP50-MEL-B MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTN4LkG5NVEh|ryP M4nkNXNCVkeHUh?=
EW-18 NE\LdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33wPGlEPTB;M{[uOFUzKM7:TR?= NEizWGxUSU6JRWK=
WM-115 NEi4N4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLBdWFjUUN3ME2zOk45ODl7IN88US=> M3jqOHNCVkeHUh?=
LU-65 NYT5OnFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrVTWM2OD1|Nz6xOFE4KM7:TR?= M1nRT3NCVkeHUh?=
NCI-H1563 NVXtZnpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjNOphKSzVyPUO3MlI1QDRizszN NHi0fVVUSU6JRWK=
DBTRG-05MG M{m3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN6LkC2PVEh|ryP MXfTRW5ITVJ?
NCI-H630 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLHTWM2OD1|OD60O|E1KM7:TR?= MWDTRW5ITVJ?
NCI-H1155 NWC2TJM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTN7LkK0NkDPxE1? NYruU|BWW0GQR1XS
OVACR-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN7LkmxPVUh|ryP NGjuc4tUSU6JRWK=
OAW-42 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7mSmlKSzVyPUSwMlQzPThizszN NHKxW|dUSU6JRWK=
JVM-2 M1vIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:5TWM2OD12MT6yOFE2KM7:TR?= MWPTRW5ITVJ?
C3A NYnDUY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnuTWM2OD12MT6zOFQ4KM7:TR?= MlnJV2FPT0WU
HT55 NUXWemZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7XXW5lUUN3ME20Nk4zQDRzIN88US=> NWHmbmw1W0GQR1XS
OVCAR-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jKOGlEPTB;NEKuNlk4PCEQvF2= NVjJ[FVkW0GQR1XS
MEG-01 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQeJlKSzVyPUSyMlQ3OTZizszN M2Xob3NCVkeHUh?=
NCI-H82 NUOyO2NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom0TWM2OD12Mz65PFkzKM7:TR?= MYXTRW5ITVJ?
JEG-3 NVnncphqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR2Lkm0O{DPxE1? MVTTRW5ITVJ?
BPH-1 M3u2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\hTWM2OD12Nj6zPVk5KM7:TR?= M1PIRXNCVkeHUh?=
MPP-89 M2j2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NViwdFZTUUN3ME20O{4zQDl6IN88US=> M3jYWHNCVkeHUh?=
ALL-PO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi0TWM2OD12Nz60NVg5KM7:TR?= MV;TRW5ITVJ?
HT Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPrTWM2OD12Nz60PVIh|ryP Mlu4V2FPT0WU
NCI-H2347 M2DOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln2TWM2OD12OD6wO|E2KM7:TR?= MojwV2FPT0WU
A2780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR7LkSyNlgh|ryP M3;qeHNCVkeHUh?=
KARPAS-299 M1LUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR7LkWxNVkh|ryP MnHnV2FPT0WU
NCI-H1651 M3LhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\0UmlEPTB;NEmuPFgzOSEQvF2= M3r0[XNCVkeHUh?=

... Click to View More Cell Line Experimental Data
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing. 		6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl
CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products3

  • SU9516 New

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A New

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib mesylate (LY2835219)

    abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID